STOCK TITAN
  1. Home
  2. News
  3. STRO

Sutro Biopharma Inc - STRO STOCK NEWS

Welcome to our dedicated news page for Sutro Biopharma (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sutro Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sutro Biopharma's position in the market.

News
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Rhea-AI Summary
Sutro Biopharma, Inc. (NASDAQ: STRO) announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at $5.18 per share, expecting gross proceeds of approximately $75.0 million. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
News
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Rhea-AI Summary
Sutro Biopharma, Inc. reported its financial results for 2023, showcasing a strong cash position of $333.7 million and key advancements in its luvelta ADC franchise, with promising data in pediatric leukemia patients. The company plans to initiate multiple trials in 2024 and expand its pipeline with new ADCs, securing collaborations for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.83%
Tags
earnings
-
News
Sutro Biopharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO Bill Newell to participate in three upcoming investor conferences to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, TD Cowen 44th Annual Health Care Conference, and Barclays 26th Annual Global Healthcare Conference. Webcasts of the presentations will be accessible through the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
News
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
Rhea-AI Summary
Sutro Biopharma, Inc. (NASDAQ: STRO) presents promising data on luvelta, a novel folate receptor-α (FolRα) targeting ADC, supporting a registration-enabling trial for platinum-resistant ovarian cancer. The potential benefit to 8 out of 10 patients with low-medium FolRα expression addresses an unmet need in the market. The company highlights luvelta's clinical activity and tolerability as a monotherapy and in combination across multiple cancers, presenting a significant commercial opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.4%
Tags
none
-
News
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) announces investor webcast to highlight clinical activity of Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC, in multiple tumor types. The company is enrolling patients in a Phase 2/3 study for platinum-resistant ovarian cancer and will discuss the potential for luvelta in a range of additional FolRα expressing cancers. The webcast will feature presentations by senior management and external key opinion leaders in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences
-
News
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) announced positive data on the anti-leukemic activity of luvelta in pediatric patients with CBF/GLIS AML. 42% of patients with ≥5% blasts achieved complete remission, and 75% of pediatric patients with <5% blasts achieved complete remission. Luvelta was well-tolerated and supported potential further development in CBF/GLIS AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
News
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO, Bill Newell, to participate in virtual fireside chat at JMP Securities Hematology and Oncology Summit on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
-
News
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) promotes Jane Chung to President and Chief Operating Officer, effective December 1, 2023. She will drive operational excellence, strategic growth, and overall business success, leading cross-functional activities to guide company-wide strategic alignment and value creation across Sutro's R&D pipeline, product portfolio, therapeutic areas of focus, and commercial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
-
News
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) reported positive financial results for Q3 2023, with $321.1 million in cash and investments. The company presented encouraging data for luvelta in endometrial cancer and announced Dr. Hans-Peter Gerber as the new CSO. The upcoming ASH 2023 will feature updated data on luvelta's anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
earnings
News
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
Rhea-AI Summary
Sutro Biopharma announces encouraging preliminary results from a Phase 1 study of luvelta in endometrial cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock STRO logo
Sutro Biopharma Inc

Nasdaq:STRO

STRO Rankings

#3540 Ranked by Market Cap
#5026 Ranked by Stock Gains
N/A Ranked by Dividends

STRO Stock Data

318.45M
48.62M
0.95%
86.15%
3.86%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About STRO

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll